Amgen(US:AMGN) ZACKSยท2025-07-18 22:51Company Performance - Amgen's stock closed at $294.76, reflecting a -1.17% change from the previous day, underperforming the S&P 500's daily loss of 0.01% [1] - Over the last month, Amgen's shares increased by 2.98%, outperforming the Medical sector's loss of 1.59% but lagging behind the S&P 500's gain of 5.37% [1] Upcoming Earnings Report - Amgen is set to release its earnings on August 5, 2025, with an expected EPS of $5.22, representing a 5.03% increase from the prior-year quarter [2] - The Zacks Consensus Estimate for revenue is projected at $8.86 billion, up 5.64% from the year-ago period [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $20.84 per share and revenue of $35.23 billion, indicating increases of +5.04% and +5.41% respectively from the last year [3] - Recent analyst estimate revisions suggest a positive outlook for Amgen's business operations and profit generation capabilities [3] Valuation Metrics - Amgen is currently trading at a Forward P/E ratio of 14.31, which is below the industry average Forward P/E of 18.7, indicating a discount relative to its peers [6] - The company has a PEG ratio of 2.7, compared to the industry average PEG ratio of 1.48, suggesting that Amgen's anticipated earnings growth is factored into its valuation [7] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 82, placing it in the top 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]